MRC/CSO Social and Public Health Sciences Unit, Institute of Health and Wellbeing, University of Glasgow, Glasgow, UK
Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.
BMJ Open. 2022 Oct 13;12(10):e062798. doi: 10.1136/bmjopen-2022-062798.
Using a surrogate endpoint as a substitute for a primary patient-relevant outcome enables randomised controlled trials (RCTs) to be conducted more efficiently, that is, with shorter time, smaller sample size and lower cost. However, there is currently no consensus-driven guideline for the reporting of RCTs using a surrogate endpoint as a primary outcome; therefore, we seek to develop SPIRIT (Standard Protocol Items: Recommendations for Interventional Trials) and CONSORT (Consolidated Standards of Reporting Trials) extensions to improve the design and reporting of these trials. As an initial step, scoping and targeted reviews will identify potential items for inclusion in the extensions and participants to contribute to a Delphi consensus process.
The scoping review will search and include literature reporting on the current understanding, limitations and guidance on using surrogate endpoints in trials. Relevant literature will be identified through: (1) bibliographic databases; (2) grey literature; (3) handsearching of reference lists and (4) solicitation from experts. Data from eligible records will be thematically analysed into potential items for inclusion in extensions. The targeted review will search for RCT reports and protocols published from 2017 to 2021 in six high impact general medical journals. Trial corresponding author contacts will be listed as potential participants for the Delphi exercise.
Ethical approval is not required. The reviews will support the development of SPIRIT and CONSORT extensions for reporting surrogate primary endpoints (surrogate endpoint as the primary outcome). The findings will be published in open-access publications.This review has been prospectively registered in the OSF Registration DOI: 10.17605/OSF.IO/WP3QH.
使用替代终点作为主要的患者相关结局替代指标,可以使随机对照试验(RCT)更有效地进行,即缩短时间、减小样本量和降低成本。然而,目前还没有共识驱动的指南来报告使用替代终点作为主要结局的 RCT;因此,我们寻求制定 SPIRIT(标准协议项目:干预试验推荐)和 CONSORT(临床试验报告的统一标准)扩展,以改进这些试验的设计和报告。作为初始步骤,范围和针对性审查将确定扩展中包含的潜在项目,并确定参与者参与 Delphi 共识过程。
范围审查将搜索并纳入文献,报告当前对替代终点在试验中的理解、局限性和指导。相关文献将通过以下方式确定:(1)文献数据库;(2)灰色文献;(3)参考文献的手工搜索;(4)征求专家意见。从合格记录中提取的数据将进行主题分析,以确定纳入扩展的潜在项目。针对性审查将搜索 2017 年至 2021 年在六份高影响力的一般医学期刊上发表的 RCT 报告和方案。将列出试验对应作者的联系方式,作为 Delphi 练习的潜在参与者。
不需要伦理批准。这些审查将支持制定 SPIRIT 和 CONSORT 扩展,以报告替代主要终点(替代终点作为主要结局)。研究结果将发表在开放获取出版物上。本综述已在 OSF 注册 DOI:10.17605/OSF.IO/WP3QH 上进行了前瞻性注册。